Clinical trial / 2015
Lactobacillus casei Shirota did not significantly alter TMAO in metabolic syndrome patients.
In an open-label randomized trial, 30 participants with metabolic syndrome were assigned to consume Lactobacillus casei Shirota three times daily (6.5 × 10^9 CFU) or standard care for 12 weeks; 28 completed the protocol. Plasma TMAO concentrations declined in both the probiotic group (4.66 ± 2.66 to 4.31 ± 2.04 μM) and controls (4.64 ± 2.75 to 4.40 ± 2.14 μM). The net changes (-0.25 ± 2.39 vs. -0.34 ± 2.23 μM) did not differ significantly between arms (p = 0.510).
- Study type
- Randomized controlled trial
- Who was studied
- 30 adults with metabolic syndrome (mean age 52-55 years)
- What was measured
- Plasma trimethylamine-N-oxide (TMAO) levels
THE PAPER
Effect of Lactobacillus casei Shirota supplementation on trimethylamine-N-oxide levels in patients with metabolic syndrome: An open-label, randomized study.
Tripolt NJ, Leber B, Triebl A, Köfeler H, Stadlbauer V, Sourij H. Atherosclerosis, 2015.
PubMed 26188537 ↗DOI 10.1016/j.atherosclerosis.2015.05.005 ↗
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.